ArticleRegenerative engineering and translational medicine2026
Multiple Drug Delivery Ability of Calcium Phosphate Scaffolds promotes Osteogenic Gene Expression in In Vitro Co‑culture Model.
Article in Regenerative engineering and translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A 'three-axis synergy' immunotherapeutic strategy for malignant bone tumors based on natural bioactives and bioactive materials.Bioactive materials · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Purpose: This study investigates the incorporation of curcumin, resveratrol, and vitamin D3 into polymer-integrated calcium phosphate (CaP) scaffolds to assess their effects on osteogenic gene expression and osteosarcoma cell viability. Polymeric micelles and a polycaprolactone-polyethylene glycol (PCL-PEG) system were utilized to enhance drug loading, release, and bioactivity. Methods: The scaffolds were functionalized with curcumin, resveratrol, and vitamin D3 using different polymeric carriers for controlled release. The release profile of these drugs was evaluated at physiological and acidic pH conditions. Osteoblast proliferation and differentiation were assessed. An osteoblast and osteoclast co-culture and RT-qPCR were performed to investigate osteogenic and osteoclastic gene expression. Resorption pit formation and Tartrate-Resistant Acid Phosphatase (TRAP) assays were conducted to analyze osteoclast activity. Lastly, osteosarcoma cell viability and morphology were examined at multiple time points to determine the anti-osteosarcoma efficacy of the drugs in vitro. Results: The drug release study shows sustained release over a period of three days. At pH 5.0, the cumulative release of curcumin, resveratrol, and vitamin D3 reached 64%, 100%, and 80%, respectively. At pH 7.4, the corresponding release values were 25% for curcumin, 69% for vitamin D3, and 92% for resveratrol. In vitro, treated scaffolds enhance osteoblast proliferation by 1.1to 1.3-fold and upregulate key osteogenic markers. Osteoclast activity was significantly reduced, with smaller resorption pits and decreased TRAP activity. Osteosarcoma viability decreases by 2.5to 2.8-fold by day 11, indicating anti-cancer efficacy of the drugs. Conclusion: The scaffolds successfully delivered bioactive compounds that promote osteoblast growth while reducing osteoclast activity and osteosarcoma cell proliferation. This multifunctional approach demonstrates the potential for enhancing bone regeneration and minimizing tumor recurrence post-surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.